Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 6
2009 6
2010 6
2011 5
2012 16
2013 6
2014 10
2015 12
2016 20
2017 19
2018 15
2019 22
2020 27
2021 33
2022 45
2023 47
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Results by year

Filters applied: . Clear all
Page 1
CDK4/6 inhibition triggers anti-tumour immunity.
Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, Winer EP, Roberts TM, Kim HJ, McAllister SS, Zhao JJ. Goel S, et al. Among authors: li bb. Nature. 2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16. Nature. 2017. PMID: 28813415 Free PMC article.
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, Howitt BE, Bronson RT, Lazo S, Roberts TM, Freeman GJ, Konstantinopoulos PA, Matulonis UA, Zhao JJ. Ding L, et al. Among authors: li bb. Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054. Cell Rep. 2018. PMID: 30540933 Free PMC article.
Reply.
Li B, Ayoo K, Eisenberg N, Lindsay TF, Roche-Nagle G. Li B, et al. J Vasc Surg. 2023 Sep;78(3):839-840. doi: 10.1016/j.jvs.2023.03.037. J Vasc Surg. 2023. PMID: 37599035 No abstract available.
Reply.
Li B, Ayoo K, Eisenberg N, Lindsay TF, Roche-Nagle G. Li B, et al. J Vasc Surg. 2024 Jan;79(1):184-186. doi: 10.1016/j.jvs.2023.09.023. Epub 2023 Sep 22. J Vasc Surg. 2024. PMID: 37741587 No abstract available.
Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.
Wu YL, Zhang L, Fan Y, Zhou J, Zhang L, Zhou Q, Li W, Hu C, Chen G, Zhang X, Zhou C, Dang T, Sadowski S, Kush DA, Zhou Y, Li B, Mok T. Wu YL, et al. Among authors: li b. Int J Cancer. 2021 May 1;148(9):2313-2320. doi: 10.1002/ijc.33399. Epub 2020 Dec 9. Int J Cancer. 2021. PMID: 33231285 Free PMC article. Clinical Trial.
KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC.
Ren S, Feng J, Ma S, Chen H, Ma Z, Huang C, Zhang L, He J, Wang C, Zhou J, Danchaivijtr P, Wang CC, Vynnychenko I, Wang K, Orlandi F, Sriuranpong V, Li B, Ge J, Dang T, Zhou C. Ren S, et al. Among authors: li b. Int J Cancer. 2023 Aug 1;153(3):623-634. doi: 10.1002/ijc.34532. Epub 2023 May 4. Int J Cancer. 2023. PMID: 37141294 Clinical Trial.
276 results